Want to see IN:ACUTAAS full AI Analyst Report?
Top Page
Acutaas Chemicals
(ACUTAAS)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹3,868.00
▲(121.38% Upside)
Action:Downgraded
Date:06/30/26
The score is primarily supported by strong FY2026 operating performance and a conservatively leveraged balance sheet. It is held back by weak cash conversion (negative free cash flow) and a demanding valuation (high P/E). Technical scoring is limited due to missing indicator data.
Positive Factors
Recent revenue and margin expansion
Sharp FY2026 top-line and margin gains indicate meaningful operating leverage and/or a favorable product mix. Sustained higher margins improve internal cash generation capacity, support reinvestment and shareholder returns, and raise long-term profitability if the mix endures.
Negative Factors
Consistent negative free cash flow
Persistent negative free cash flow suggests the business requires ongoing heavy reinvestment or faces working-capital drains. Over time this can constrain balance sheet flexibility, limit debt reduction or payouts, and force external financing during cyclical stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Recent revenue and margin expansion
Sharp FY2026 top-line and margin gains indicate meaningful operating leverage and/or a favorable product mix. Sustained higher margins improve internal cash generation capacity, support reinvestment and shareholder returns, and raise long-term profitability if the mix endures.
Read all positive factors
Acutaas Chemicals (ACUTAAS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹293.29B
Dividend Yield0.09%
Average Volume (3M)14.81K
Price to Earnings (P/E)82.4
Beta (1Y)1.40
Revenue Growth33.02%
EPS Growth122.92%
CountryIN
Employees879
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)27.88
Shares Outstanding81,871,124
10 Day Avg. Volume15,850
30 Day Avg. Volume14,806
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)12.67
Price to Sales (P/S)15.64
P/FCF Ratio-733.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹3,773.00Price Target Upside115.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)53.3
Revenue Forecast (FY)₹17.53B
Acutaas Chemicals Business Overview & Revenue Model
Company Description
Based in Surat, India, Acutaas Chemicals Limited, founded in 2004, is engaged in the development, production, and global distribution of pharmaceutical intermediates. These crucial compounds are utilized in both regulated and generic active pharma...
Acutaas Chemicals Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.83B | 13.39B | 10.07B | 7.17B | 5.18B | 3.41B |
| Gross Profit | 3.58B | 6.20B | 2.73B | 2.63B | 1.94B | 1.22B |
| EBITDA | 2.66B | 4.80B | 2.49B | 1.04B | 1.08B | 811.14M |
| Net Income | 1.80B | 3.56B | 1.59B | 427.73M | 719.46M | 539.99M |
Balance Sheet | ||||||
| Total Assets | 16.96B | 19.84B | 15.49B | 10.96B | 6.59B | 4.13B |
| Cash, Cash Equivalents and Short-Term Investments | 2.41B | 2.25B | 2.49B | 533.12M | 615.46M | 26.85M |
| Total Debt | 164.97M | 355.96M | 129.39M | 2.17B | 8.44M | 1.37B |
| Total Liabilities | 2.57B | 2.73B | 2.29B | 4.13B | 1.37B | 2.46B |
| Stockholders Equity | 14.14B | 16.54B | 13.10B | 6.74B | 5.22B | 1.67B |
Cash Flow | ||||||
| Free Cash Flow | -482.21M | -285.38M | -717.02M | -1.56B | -424.18M | -794.33M |
| Operating Cash Flow | 2.09B | 2.99B | 1.23B | 1.25B | -86.60M | 271.45M |
| Investing Cash Flow | -848.93M | -2.74B | -2.35B | -3.68B | -1.24B | -1.00B |
| Financing Cash Flow | -93.77M | 53.74M | 2.67B | 2.39B | 1.40B | 721.08M |
Acutaas Chemicals Technical Analysis
Positive
1747.20
Price Trends
3163.02
Positive
2733.69
Positive
2217.23
Positive
Market Momentum
110.54
Positive
62.47
Neutral
47.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ACUTAAS, the sentiment is Positive. The current price of 1747.2 is below the 20-day moving average (MA) of 3439.88, below the 50-day MA of 3163.02, and below the 200-day MA of 2217.23, indicating a bullish trend. The MACD of 110.54 indicates Positive momentum. The RSI at 62.47 is Neutral, neither overbought nor oversold. The STOCH value of 47.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ACUTAAS.
Acutaas Chemicals Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹180.08B | 26.55 | ― | 0.41% | 12.36% | 40.19% | |
68 Neutral | ₹293.29B | 82.37 | ― | 0.09% | 33.02% | 122.92% | |
67 Neutral | ₹136.82B | 30.87 | ― | 0.48% | -0.95% | 9.51% | |
59 Neutral | ₹198.82B | 90.59 | ― | ― | 37.53% | 38.70% | |
57 Neutral | ₹144.57B | 84.10 | ― | 0.06% | 64.44% | 77.60% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₹183.00B | 43.63 | ― | 0.26% | 14.15% | 26.69% |
* General Sector Average
IN:ACUTAAS
Acutaas Chemicals
3,582.30
2,375.63
196.87%
IN:AARTIIND
AARTI Industries Ltd
504.50
49.71
10.93%
IN:AETHER
Aether Industries Ltd.
1,498.15
677.85
82.63%
IN:ANURAS
Anupam Rasayan India Ltd.
1,269.85
121.35
10.57%
IN:ATUL
Atul Limited
6,116.55
-1,169.35
-16.05%
IN:VINATIORGA
Vinati Organics Limited
1,319.85
-674.56
-33.82%
Acutaas Chemicals Corporate Events
Tax Authority Conducts Search at Acutaas Chemicals’ Surat Facilities
Jun 22, 2026
Acutaas Chemicals disclosed that the Central Goods Service Tax and Central Excise Anti-evasion Department in Surat initiated an inspection and search at its registered office and Sachin manufacturing unit under Section 67(2) of the Central Goods ...
Acutaas Chemicals Files SEBI Compliance Certificate, Reports No Demat Activity in Q4 FY26
Apr 2, 2026
Acutaas Chemicals Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The registrar MUFG Intime India Private Limited confirmed t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.